Bluejay Diagnostics (BJDX) Research & Development (2020 - 2026)

Bluejay Diagnostics has disclosed Research & Development across 7 years of filings, most recently posting $811837.0 for Q1 2026.

• Research & Development for Q1 2026 came in at $811837.0, up 3.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.1 million (up 5.15% YoY), and the FY2025 annual result was $3.0 million, down 12.25% from the prior year.
• Research & Development came in at $811837.0 for Q1 2026 at Bluejay Diagnostics, up from $586144.0 in the prior quarter.
• In the past five years, Research & Development ranged from a high of $1.7 million in Q2 2023 to a low of $551655.0 in Q3 2024.
• The 5-year median for Research & Development is $889896.0 (2025), against an average of $1.0 million.
• Across the five-year window, Research & Development jumped 2772.91% in 2022 and tumbled 60.52% in 2024, its largest moves.
• Bluejay Diagnostics' Research & Development stood at $1.3 million in 2022, then fell by 2.65% to $1.3 million in 2023, then sank by 56.94% to $553997.0 in 2024, then climbed by 5.8% to $586144.0 in 2025, then surged by 38.5% to $811837.0 in 2026.
• The last three Research & Development figures came in at $811837.0 (Q1 2026), $586144.0 (Q4 2025), and $785608.0 (Q3 2025), per Business Quant data.